MedPath
FDA Approval

IMFINZI

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
June 16, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Durvalumab(120 mg in 2.4 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

AstraZeneca PLC

230790719

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

IMFINZI

Product Details

NDC Product Code
0310-4500
Application Number
BLA761069
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
June 16, 2023
HISTIDINEInactive
Code: 4QD397987EClass: IACTQuantity: 4.8 mg in 2.4 mL
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACTQuantity: 0.5 mg in 2.4 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
Code: 28X28X9OKVClass: ACTIBQuantity: 120 mg in 2.4 mL
TREHALOSE DIHYDRATEInactive
Code: 7YIN7J07X4Class: IACTQuantity: 250 mg in 2.4 mL
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATEInactive
Code: X573657P6PClass: IACTQuantity: 6.5 mg in 2.4 mL

IMFINZI

Product Details

NDC Product Code
0310-4611
Application Number
BLA761069
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
June 16, 2023
Code: 28X28X9OKVClass: ACTIBQuantity: 500 mg in 10 mL
HISTIDINEInactive
Code: 4QD397987EClass: IACTQuantity: 20 mg in 10 mL
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATEInactive
Code: X573657P6PClass: IACTQuantity: 27 mg in 10 mL
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACTQuantity: 2 mg in 10 mL
TREHALOSE DIHYDRATEInactive
Code: 7YIN7J07X4Class: IACTQuantity: 1040 mg in 10 mL
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath